Conatus Pharmaceuticals (CNAT) Stock Rating Lowered by Stifel Nicolaus

Conatus Pharmaceuticals (NASDAQ:CNAT) was downgraded by equities research analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating in a report issued on Thursday, MarketBeat reports. They presently have a $4.00 target price on the biotechnology company’s stock. Stifel Nicolaus’ target price indicates a potential upside of 133.92% from the stock’s current price.

Several other research firms have also issued reports on CNAT. Oppenheimer set a $14.00 target price on Conatus Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, October 1st. ValuEngine raised Conatus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, September 22nd. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Conatus Pharmaceuticals in a research report on Monday, November 5th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $11.12.

CNAT opened at $1.71 on Thursday. Conatus Pharmaceuticals has a 12-month low of $1.52 and a 12-month high of $7.95. The company has a current ratio of 2.39, a quick ratio of 2.39 and a debt-to-equity ratio of 0.83. The stock has a market cap of $58.71 million, a P/E ratio of -2.80 and a beta of 1.99.

Conatus Pharmaceuticals (NASDAQ:CNAT) last posted its earnings results on Thursday, November 1st. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.15). Conatus Pharmaceuticals had a negative return on equity of 83.99% and a negative net margin of 52.77%. The firm had revenue of $7.67 million for the quarter, compared to analyst estimates of $9.70 million. Equities analysts forecast that Conatus Pharmaceuticals will post -0.6 earnings per share for the current year.

A number of hedge funds have recently bought and sold shares of CNAT. Artal Group S.A. acquired a new stake in Conatus Pharmaceuticals in the 3rd quarter valued at about $2,900,000. BlackRock Inc. raised its position in Conatus Pharmaceuticals by 13.4% in the 3rd quarter. BlackRock Inc. now owns 1,623,958 shares of the biotechnology company’s stock valued at $9,419,000 after purchasing an additional 191,287 shares in the last quarter. Alambic Investment Management L.P. raised its position in Conatus Pharmaceuticals by 207.0% in the 2nd quarter. Alambic Investment Management L.P. now owns 264,665 shares of the biotechnology company’s stock valued at $1,133,000 after purchasing an additional 178,461 shares in the last quarter. Paloma Partners Management Co acquired a new stake in Conatus Pharmaceuticals in the 2nd quarter valued at about $547,000. Finally, LMR Partners LLP acquired a new stake in Conatus Pharmaceuticals in the 2nd quarter valued at about $311,000. 31.93% of the stock is currently owned by institutional investors.

About Conatus Pharmaceuticals

Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.

Featured Article: Why is the LIBOR significant?

Analyst Recommendations for Conatus Pharmaceuticals (NASDAQ:CNAT)

Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply